Protagenic Therapeutics, Inc. (PTIX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | -25.14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 100% | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 12.57K | 12.57K | 12.57K | 25.14K | 12.57K | 12.57K | 12.57K | 26.62K | 1.42K | 91 | 0 |
| COGS % of Revenue | - | - | - | - | -100% | - | - | - | - | - | - | - |
| Gross Profit | 0 | -12.57K | -12.57K | -12.57K | -50.29K | -12.57K | -12.57K | -12.57K | -26.62K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | 200% | - | - | - | - | - | - | - |
| Gross Profit Growth % | 100% | -0.01% | 0% | 0% | -88.92% | - | - | - | - | - | - | - |
| Operating Expenses | 925.1K | 1.1M | 2.33M | 1.45M | 1.64M | 652.07K | 1.67M | 1.74M | 1.21M | 1.43M | 1.14M | 739.29K |
| OpEx % of Revenue | - | - | - | - | -6534.62% | - | - | - | - | - | - | - |
| Selling, General & Admin | 154.82K | 159.91K | 814.26K | 567.74K | 739.82K | 287.88K | 453.3K | 277.61K | 200.8K | 307.68K | 307.36K | 391.26K |
| SG&A % of Revenue | - | - | - | - | -2942.43% | - | - | - | - | - | - | - |
| Research & Development | 153.79K | 273.23K | 394.11K | 880.37K | 903.36K | 364.18K | 1.21M | 1.46M | 1.01M | 1.12M | 836.38K | 348.03K |
| R&D % of Revenue | - | - | - | - | -3592.9% | - | - | - | - | - | - | - |
| Other Operating Expenses | 616.5K | 668.15K | 1000K | -108 | -178 | 0 | -298 | -613 | 201 | 0 | 0 | 0 |
| Operating Income | -925.1K | -1.11M | -2.34M | -1.45M | -1.64M | -652K | -1.67M | -1.74M | -1.21M | -1.43M | -1.14M | -739K |
| Operating Margin % | - | - | - | - | 6534.62% | - | - | - | - | - | - | - |
| Operating Income Growth % | 43.69% | -70.84% | -40.64% | 16.69% | -35.56% | 54.47% | -45.75% | -135.18% | -84.76% | -54.98% | -79.55% | 44.89% |
| EBITDA | -912.53K | -1.1M | -2.33M | -1.44M | -1.63M | -639.43K | -1.65M | -1.73M | -1.19M | -1.43M | -1.14M | -738.91K |
| EBITDA Margin % | - | - | - | - | 6484.62% | - | - | - | - | - | - | - |
| EBITDA Growth % | 44.03% | -72.23% | -40.95% | 16.81% | -37.54% | 55.3% | -44.66% | -133.51% | -80.71% | -2384401.67% | -350713.19% | - |
| D&A (Non-Cash Add-back) | 12.57K | 12.57K | 12.57K | 12.57K | 12.57K | 12.57K | 12.57K | 12.57K | 26.62K | 1.42K | 91 | 90 |
| EBIT | -925.1K | -869.49K | -4.82M | -1.45M | -1.55M | -641K | -1.61M | -1.74M | -1.64M | -1.36M | -1.18M | -687K |
| Net Interest Income | 23.83K | 34.34K | -238.73K | 8.1K | 9.03K | 11.28K | 9.29K | 13.87K | 40.8K | 37.26K | 53.1K | 25.63K |
| Interest Income | 23.83K | 0 | 0 | 8.1K | 9.03K | 11.28K | 9.29K | 13.87K | 53.66K | 69.22K | 84.71K | 56.89K |
| Interest Expense | 0 | 34.34K | 238.73K | 0 | 0 | 0 | 0 | 0 | 12.85K | 31.96K | 31.61K | 31.26K |
| Other Income/Expense | 3.14M | 244.37K | -2.71M | 8.1K | 89.44K | 11.28K | 60.83K | 14.06K | -464K | 35.09K | -65.85K | 21.2K |
| Pretax Income | 2.21M | -869.5K | -5.06M | -1.44M | -1.55M | -641K | -1.61M | -1.72M | -1.68M | -1.4M | -1.21M | -718K |
| Pretax Margin % | - | - | - | - | 6180.65% | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 2.21M | -869.5K | -5.06M | -1.44M | -1.55M | -641K | -1.61M | -1.72M | -1.68M | -1.4M | -1.21M | -718K |
| Net Margin % | - | - | - | - | 6180.65% | - | - | - | - | - | - | - |
| Net Income Growth % | 242.26% | -35.65% | -214.72% | 16.47% | 7.28% | 54.12% | -32.81% | -140.11% | -176.11% | -56.09% | -81.41% | 46.78% |
| Net Income (Continuing) | 2.21M | -869.5K | -5.06M | -1.44M | -1.55M | -641K | -1.61M | -1.72M | -1.68M | -1.4M | -1.21M | -718K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.14 | -0.47 | -1.37 | -2.75 | -0.24 | -0.14 | -0.36 | -5.44 | -0.38 | -0.32 | -0.28 | -0.17 |
| EPS Growth % | 575% | -235.71% | -280.56% | 49.45% | 36.84% | 56.25% | -28.57% | -3100% | -171.43% | -52.38% | -86.67% | 46.88% |
| EPS (Basic) | 1.14 | -0.47 | -1.37 | -2.75 | -0.24 | -0.14 | -0.36 | -0.39 | -0.38 | -0.32 | -0.28 | -0.17 |
| Diluted Shares Outstanding | 1.93M | 1.85M | 3.7M | 523.18K | 6.5M | 4.47M | 4.44M | 4.43M | 4.38M | 4.33M | 4.33M | 4.32M |
| Basic Shares Outstanding | 1.93M | 1.85M | 3.7M | 523.18K | 6.5M | 4.47M | 4.44M | 4.43M | 4.38M | 4.33M | 4.33M | 4.22M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |